Publications by authors named "Kehe Chen"

Claim this Profile
A
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.
Rongrui Liu, Xianli Yin, Yuxian Bai, Haijun Zhong, Feng Ye, Kehe Chen

Eur J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.
Chuanhua Zhao, Yanqiao Zhang, Gang Wang, Jinfang Zheng, Weiqing Chen, Ying Cheng, Guicheng Wu, Kehe Chen, Shaojun Chen, Jian Chen, Chengwu Zhang

Signal Transduct Target Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial.
Feng Bi, Jian Dong, Chuan Jin, Zuoxing Niu, Wenhui Yang, Kehe Chen

J Hematol Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial.
Zi-Xian Wang, Junjie Peng, Xinjun Liang, Ying Cheng, Yanhong Deng, Kehe Chen

Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).
Xinan Sheng, Dingwei Ye, Aiping Zhou, Xin Yao, Hong Luo, Peng Chen, Cheng Fu, Kehe Chen

Eur J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Downregulation of LncRNA SNHG7 Sensitizes Colorectal Cancer Cells to Resist Anlotinib by Regulating miR-181a-5p/GATA6.
Deng Pan, Kehe Chen, Ping Chen, Yu Liu, Yingying Wu

Gastroenterol Res Pract· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.
Shukui Qin, Jin Li, Haijun Zhong, Chuan Jin, Lili Chen, Kehe Chen, Xicheng Wang

Br J Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.
Shukui Qin, Jin Li, Haijun Zhong, Chuan Jin, Lili Chen, Kehe Chen, Xicheng Wang

Br J Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of circulating tumor cells in predicating the outcomes of patients with colorectal cancer.
Kehe Chen, Zhenxiang Chen, Mei Ou, Junping Wang, Xiao Huang

Clinics (Sao Paulo)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
Shukui Qin, Jin Li, Yuxian Bai, Yongqian Shu, Wei Li, Ying Cheng, Kehe Chen

BioDrugs· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib.
Bo Yuan, Jun Zhao, Chengzhi Zhou, Xiumei Wang, Bo Zhu, Zhengtang Chen, Kehe Chen, Rongrong Chen

Front Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells.
Kehe Chen, Haiming Wei, Jinfei Pan, Zhenxiang Chen, Deng Pan

Eur J Pharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Docosahexaenoic acid inhibits aflatoxin B1-induced migration and invasion in hepatocellular carcinoma cells in vitro].
Ke-He Chen, Ting Gao, Jin-Fei Pan, Hai-Ming Wei, Chun-Hong Jia, Zhen-Xiang Chen

Nan Fang Yi Ke Da Xue Xue Bao· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of prognostic biomarkers for response to radiotherapy by DNA microarray in nasopharyngeal carcinoma patients.
Shu Yang, Jiaxin Chen, Yi Guo, Hui Lin, Zheng Zhang, Jinjian Cheng, Kehe Chen

Int J Oncol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case report of scrotal carcinoma and review of the literature.
Wei Peng, Guosheng Feng, Heming Lu, Jiaxin Chen, Kehe Chen

Case Rep Oncol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Construction of recombinant lentiviral vectors containing Rheb gene and its mutant Rheb'D60K gene and their expression in human liver cancer cells].
Ke-He Chen, Bo Liang, Zhen-Hong Zou, Ze-Long Han, Jin-Fei Pan

Nan Fang Yi Ke Da Xue Xue Bao· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of reliable reference genes for gene expression study in nasopharyngeal carcinoma.
Yi Guo, Jia-xin Chen, Shu Yang, Xu-ping Fu, Zheng Zhang, Ke-he Chen

Acta Pharmacol Sin· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis